Prevention of HIV-associated opportunistic infections and diseases in the age of highly active antiretroviral therapy.
about
Design, Synthesis, and Molecular Modeling of Novel Pyrido[2,3- d ]pyrimidine Analogues As Antifolates; Application of Buchwald–Hartwig Aminations of HeterocyclesEfficiency of diagnostic methods for correlation between prevalence of enteric protozoan parasites and HIV/AIDS status--an experience of a tertiary care hospital in East Delhi.2,4-Diamino-5-methyl-6-substituted arylthio-furo[2,3-d]pyrimidines as novel classical and nonclassical antifolates as potential dual thymidylate synthase and dihydrofolate reductase inhibitors.Long-Term Trends in Esophageal Candidiasis Prevalence and Associated Risk Factors with or without HIV Infection: Lessons from an Endoscopic Study of 80,219 PatientsPorphyromonas gingivalis, Treponema denticola, and Tannerella forsythia: the "red complex", a prototype polybacterial pathogenic consortium in periodontitis.Prevalence of intestinal parasites and associated risk factors among HIV/AIDS patients with pre-ART and on-ART attending dessie hospital ART clinic, Northeast EthiopiaUnusual Enterocytozoon bieneusi genotypes and Cryptosporidium hominis subtypes in HIV-infected patients on highly active antiretroviral therapy.The effect of 5-alkyl modification on the biological activity of pyrrolo[2,3-d]pyrimidine containing classical and nonclassical antifolates as inhibitors of dihydrofolate reductase and as antitumor and/or antiopportunistic infection agents.Immune deficiency in HIV-1 infection: novel therapeutic approaches targeting innate and adaptive responses.Dynamics of T-cell subsets and their relationship with oral and systemic opportunistic infections in HIV/AIDS patients during the first year of HAART in Guangxi, China.Risk factors for intestinal parasitosis among antiretroviral-treated HIV/AIDS patients in Ethiopia.Short-term safety and tolerability of a once-daily fixed-dose abacavir-lamivudine combination versus twice-daily dosing of abacavir and lamivudine as separate components: findings from the ALOHA study.
P2860
Q27677848-DF67C26B-3C93-4FC4-8ECA-B182EAA8DDABQ30407687-4ABEF45B-7612-4B68-B371-94C8E25C9A71Q33639893-498B9B59-9E38-4A2A-AC54-52890C511158Q35711907-3034414F-7E67-4663-878C-D8D42B55EB44Q36107786-0174F923-C6A5-471D-902B-A6ACCC4D3D2DQ36688242-A6D8EB70-A6ED-4AA7-884C-C21EC1B11213Q37107937-51029B7A-A49C-4A00-972D-DC6073843993Q37380738-47DD48A7-D70C-42AC-BD69-42862DBAFBA1Q40377124-83A240E8-E3AA-42D1-9A0E-15E9001C00E9Q41427454-7BF7311F-73F7-4E2D-8F9D-CA5AC4D4097BQ43313076-9AB203E7-333E-4C94-BC45-51D3D0FB6B3AQ46738435-901C8E24-DE55-4D8D-A38A-3C436267542D
P2860
Prevention of HIV-associated opportunistic infections and diseases in the age of highly active antiretroviral therapy.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Prevention of HIV-associated o ...... active antiretroviral therapy.
@ast
Prevention of HIV-associated o ...... active antiretroviral therapy.
@en
type
label
Prevention of HIV-associated o ...... active antiretroviral therapy.
@ast
Prevention of HIV-associated o ...... active antiretroviral therapy.
@en
prefLabel
Prevention of HIV-associated o ...... active antiretroviral therapy.
@ast
Prevention of HIV-associated o ...... active antiretroviral therapy.
@en
P2860
P356
P1476
Prevention of HIV-associated o ...... active antiretroviral therapy
@en
P2093
Patrick Willemot
P2860
P304
P356
10.1586/14787210.2.4.521
P50
P577
2004-08-01T00:00:00Z